Navigation Links
Cleveland Clinic Physicians to Present at Medical Conference in Panama, July 11-12
Date:7/7/2008

Seventh Annual Joint Conference With Centro Medical Paitilla to Focus on

Neuroscience

CLEVELAND, July 7 /PRNewswire/ -- A group of physicians from Cleveland Clinic will travel to Panama in mid July to present at the seventh annual Joint Cleveland Clinic - Centro Medico Paitilla Scientific Meeting. The subject of this year's conference is the Central Nervous System: Benign and Malignant Tumors.

The conference takes place July 11-12 at the Sheraton Hotel in Panama City, Panama. More than 300 medical professionals including neurologists, neurosurgeons, radiation oncologists, spinal surgeons, nurses and insurance representatives are expected to attend the annual conference.

"Cleveland Clinic is proud to participate is this highly regarded conference which every year provides our physicians with the opportunity to share the latest in medical research and clinical practice with medical professionals in Panama and neighboring Central American countries," said Atul Mehta, M.D., Director of the Center for International Medical Education at Cleveland Clinic. "Medical education, in addition to research and state-of-the-art clinical care, is at the core of Cleveland Clinic's mission. By participating in conferences like this, we strive to benefit patients worldwide."

The Cleveland Clinic physicians presenting at the conference are: Lilyana Angelov, M.D., Section Head of Spinal Radiosurgery and Director the Clinic's Brain Tumor Institute's Central Nervous System Lymphoma Program at the Clinic; John Suh, M.D., Chairman of the Clinic's Department of Radiation Oncology; and Edward Benzel, M.D., Chairman of the Department of Neurological Surgery and Director of the Center for Spine Health, also at Cleveland Clinic.

Founded in 1975, Centro Medico Paitilla, in Panama City, Panama, is a private healthcare facility of tertiary care, best known for its Intensive Care Unit for adults and neonates, and its Oncology C
'/>"/>

SOURCE Cleveland Clinic
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Cleveland-based Health Care Tech Company Within3 Names New CEO
2. Cardiovascular Technologies to be Highlighted at 5th Annual Cleveland Clinic Medical Innovation Summit, Oct. 1-3
3. Cleveland Clinic Press Releases Journal-Writing Book Write for Life: Healing Body, Mind, and Spirit Through Journal Writing by Sheppard B. Kominars, Ph.D.
4. Cleveland Clinic and The Larry King Cardiac Foundation Partner to Provide Heart Surgery to Those in Need
5. Cleveland Clinic Unveils Top 10 Medical Innovations For 2008
6. New Cleveland Clinic Press Healthy Cookbook Helps Diabetic Kids
7. Cleveland Clinic Press Releases Consumer Health Book About Treating Headache Pain
8. Announcing Always Best Care Senior Services Expansion Into Cleveland, Ohio
9. Millennium Biotechnologies Inc. Signs Five Year $20,000,000 Purchase Agreement with Provider Services Inc. of Cleveland, Ohio
10. World Firsts by Cleveland Clinic Urologists
11. Wellness Experts From Cleveland Clinic Set for 2008 Crystal Voyages
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2008)...ican women using Carraguard had no decrease in inf...4 (HealthDay News) -- A microbicidal vaginal gel c...fection. , That,s the conclusion of a study tha...gative women at three sites in South Africa. , ...o gel and told to use one applicator of gel and a ...
(Date:12/4/2008)..., Dec. 4 Aurora Health Care is ram... D supplements. Aurora,s Care Management,Clinical...ucate all Aurora,caregivers about the benefits of...g evidence that higher Vitamin D levels may improv...porosis, certain muscle conditions and,seasonal d...
(Date:12/4/2008)...N, Dec. 4 The U.S. Gove...Development (USAID), is providing an additional $6...abwe. This assistance is in addition to the $4 mi...gram USAID is already implementing in Zimbabwe. ,... working alongside the international community to ...
(Date:12/4/2008)...cts similar to those seen with standard dose of da...c. 4 (HealthDay News) -- A high dose of the chemot...tients with previously untreated acute myeloid leu...red by the U.S. National Cancer Institute (NCI) sh...row. This study included 633 patients, aged 16 to ...
Breaking Medicine News(10 mins):Health News:Experimental Vaginal Gel Doesn't Ward Off HIV 2Health News:Aurora Health Care Urges All Wisconsin Residents to Take Vitamin D 2Health News:USAID Increases Assistance for Zimbabwe Cholera Outbreak 2Health News:Higher Chemo Drug Dose Prolongs Lives of Leukemia Patients 2
...ming at getting the children in northern communiti...h Promotion Minister, Jim Watson, the government w... carrot sticks, apples and other fresh fruit and v... children in elementary schools in Northern Ontari...
... found to have a role in the treatment of lung dis...cent research. // The results of the study have b...and Journal of Medicine, which has revealed that t...tment of cancer could slightly improve lung functi...
...o a vasectomy reversal could be at an increased ri...ead to birth defects in children. // The research...ersity, Bangkok, Thailand. The study was conducted...rocedure which does not interfere with sperm produ...
...daily doses of insulin injections. However in peop...f the pancreatic tissue// could help solve the pro...lindness, amputation, kidney failure, and heart di...early enough organ donors available for transplant...
Other Medicine News:Health News:Obesity Tackled at School Level 2Health News:Cancer Drug to Treat Scleroderma Lung Disease 2Health News:Vasectomy Reversal to Lead to Birth Defects 2Health News:Transplanted Pancreatic Tissue Could Help Diabetics 2
(Date:12/2/2008)...RNewswire-USNewswire/ -- Researchers using functio... in the area of the brain,responsible for suppres... from,stress-related psychiatric disorders. Resul...nual meeting of the Radiological Society of North ... depression and other stress-related disorders,t...
(Date:12/2/2008)... 2 Horizon Therapeutics, Inc., a,...nounced that two pivotal,Phase 3 trials evaluatin...501,met all primary endpoints. HZT-501, a novel,...ining ibuprofen and famotidine, demonstrated a,st... of non-steroidal,anti-inflammatory drug (NSAID)-...
(Date:12/1/2008)... TargeGen has announced that an ora...ti-center, US-based clinical,trial of TG101348 in...duled at,the 2008 American Society of Hematology ...ion are as follows:, Title: A P... JAK2-Selective Inhibitor, ...
(Date:12/1/2008)...s still the best policy , , ROCHESTER, Min...from Mayo Clinic finds the use of the drug therapy...titis, an acute inflammation of the liver caused b... the study are published in the December issue of ... ). , , VIDEO ALERT: Additional audio and ...
Breaking Medicine Technology:Stress-Related Disorders Affect Brain's Processing of Memory 2Stress-Related Disorders Affect Brain's Processing of Memory 3Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 2Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 3Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 4Mayo Clinic Seeks New Therapies for Alcoholic Hepatitis 2Mayo Clinic Seeks New Therapies for Alcoholic Hepatitis 3Oncolytics Biotech Inc Announces 2008 First Quarter Results 5000 1Oncolytics Biotech Inc Announces 2008 First Quarter Results 5000 2Oncolytics Biotech Inc Announces 2008 First Quarter Results 5000 3Oncolytics Biotech Inc Announces 2008 First Quarter Results 5000 4Oncolytics Biotech Inc Announces 2008 First Quarter Results 5000 5Oncolytics Biotech Inc Announces 2008 First Quarter Results 5000 6Oncolytics Biotech Inc Announces 2008 First Quarter Results 5000 7Oncolytics Biotech Inc Announces 2008 First Quarter Results 5000 8Oncolytics Biotech Inc Announces 2008 First Quarter Results 5000 9Oncolytics Biotech Inc Announces 2008 First Quarter Results 5000 10Oncolytics Biotech Inc Announces 2008 First Quarter Results 5000 11Oncolytics Biotech Inc Announces 2008 First Quarter Results 5000 12Oncolytics Biotech Inc Announces 2008 First Quarter Results 5000 13Oncolytics Biotech Inc Announces 2008 First Quarter Results 5000 14Oncolytics Biotech Inc Announces 2008 First Quarter Results 5000 15Oncolytics Biotech Inc Announces 2008 First Quarter Results 5000 16Oncolytics Biotech Inc Announces 2008 First Quarter Results 5000 17Oncolytics Biotech Inc Announces 2008 First Quarter Results 5000 18Oncolytics Biotech Inc Announces 2008 First Quarter Results 5000 19Oncolytics Biotech Inc Announces 2008 First Quarter Results 5000 20Oncolytics Biotech Inc Announces 2008 First Quarter Results 5000 21Oncolytics Biotech Inc Announces 2008 First Quarter Results 5000 22Oncolytics Biotech Inc Announces 2008 First Quarter Results 5000 23Oncolytics Biotech Inc Announces 2008 First Quarter Results 5000 24Oncolytics Biotech Inc Announces 2008 First Quarter Results 5000 25Oncolytics Biotech Inc Announces 2008 First Quarter Results 5000 26Oncolytics Biotech Inc Announces 2008 First Quarter Results 5000 27Oncolytics Biotech Inc Announces 2008 First Quarter Results 5000 28Oncolytics Biotech Inc Announces 2008 First Quarter Results 5000 29Oncolytics Biotech Inc Announces 2008 First Quarter Results 5000 30Oncolytics Biotech Inc Announces 2008 First Quarter Results 5000 31Oncolytics Biotech Inc Announces 2008 First Quarter Results 5000 32Oncolytics Biotech Inc Announces 2008 First Quarter Results 5000 33Cadence Pharmaceuticals CEO Ted Schroeder to Present at Three Investment Conferences During the Month of May 2008 4998 1Cadence Pharmaceuticals CEO Ted Schroeder to Present at Three Investment Conferences During the Month of May 2008 4998 2ISTA Pharmaceuticals Announces New Phase III Clinical Findings to Support Bepreve NDA Filing 1948 1ISTA Pharmaceuticals Announces New Phase III Clinical Findings to Support Bepreve NDA Filing 1948 2ISTA Pharmaceuticals Announces New Phase III Clinical Findings to Support Bepreve NDA Filing 1948 3ISTA Pharmaceuticals Announces New Phase III Clinical Findings to Support Bepreve NDA Filing 1948 4Genetic Changes May Dictate Course of Acute Myeloid Leukemia 18089 1Genetic Changes May Dictate Course of Acute Myeloid Leukemia 18089 2Genetic Changes May Dictate Course of Acute Myeloid Leukemia 18089 3
...IDGE, Mass., July 06, 2007 /PRNewswire-FirstCall/ ...m the first of two,Phase 3 clinical studies to ass...n investigational, non-antibiotic, polymer,therapy...d diarrhea,(CDAD). The second Phase 3 study of tol...pected later this year. , In this first Phase 3 st...
..., Switzerland--(BUSINESS WIRE)--Jul 9, 2007 - ZIOP...positive interim data,from an ongoing phase II tri...treat advanced sarcoma patients was presented at t...ting held July 5-8,2007 in Lugano, Switzerland. T...O-201) In Advanced Sarcoma," was presented by,Rash...
Other Medicine Technology:Genzyme Announces Data from First Phase 3 Study of Tolevamer in,Patients with C. difficile Associated Diarrhea 2Genzyme Announces Data from First Phase 3 Study of Tolevamer in,Patients with C. difficile Associated Diarrhea 3Genzyme Announces Data from First Phase 3 Study of Tolevamer in,Patients with C. difficile Associated Diarrhea 4Positive ZIO-201 Interim Phase II Sarcoma Data Presented at,European Society for Medical Oncology 2Positive ZIO-201 Interim Phase II Sarcoma Data Presented at,European Society for Medical Oncology 3
Non-sterile Silicone Tubing
Anodized aluminum. Durable and lightweight with built-in protection against rust. Security locks ensure against accidental opening. Silicone matting/V-strips and bumper guards hold instruments in pla
Diamond knife tray with silicone inserts to securely hold the diamond knife.
Size: 6 x 10 inches. Depth: 7 inches. Sterilizable plastic tray with silicone matting for supporting and protecting instruments.
Medicine Products: